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Abstract
Background: The Acute Physiology and Chronic Health Evaluation (APACHE) III prognostic system has
not been previously validated in patients admitted to the intensive care unit (ICU) after orthotopic liver
transplantation (OLT). We hypothesized that APACHE III would perform satisfactorily in patients after
OLT
Methods: A retrospective cohort study was performed. Patients admitted to the ICU after OLT between
July 1996 and May 2008 were identified. Data were abstracted from the institutional APACHE III and liver
transplantation databases and individual patient medical records. Standardized mortality ratios (with 95%
confidence intervals) were calculated by dividing the observed mortality rates by the rates predicted by
APACHE III. The area under the receiver operating characteristic curve (AUC) and the Hosmer-
Lemeshow C statistic were used to assess, respectively, discrimination and calibration of APACHE III.
Results: APACHE III data were available for 918 admissions after OLT. Mean (standard deviation [SD])
APACHE III (APIII) and Acute Physiology (APS) scores on the day of transplant were 60.5 (25.8) and 50.8
(23.6), respectively. Mean (SD) predicted ICU and hospital mortality rates were 7.3% (15.4) and 10.6%
(18.9), respectively. The observed ICU and hospital mortality rates were 1.1% and 3.4%, respectively. The
standardized ICU and hospital mortality ratios with their 95% C.I. were 0.15 (0.07 to 0.27) and 0.32 (0.22
to 0.45), respectively.
There were statistically significant differences in APS, APIII, predicted ICU and predicted hospital mortality
between survivors and non-survivors. In predicting mortality, the AUC of APACHE III prediction of
hospital death was 0.65 (95% CI, 0.62 to 0.68). The Hosmer-Lemeshow C statistic was 5.288 with a p value
of 0.871 (10 degrees of freedom).
Conclusion: APACHE III discriminates poorly between survivors and non-survivors of patients admitted
to the ICU after OLT. Though APACHE III has been shown to be valid in heterogenous populations and
in certain groups of patients with specific diagnoses, it should be used with caution – if used at all – in
recipients of liver transplantation.
Published: 29 July 2009
BMC Surgery 2009, 9:11 doi:10.1186/1471-2482-9-11
Received: 20 March 2009
Accepted: 29 July 2009
This article is available from: http://www.biomedcentral.com/1471-2482/9/11
© 2009 Keegan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Surgery 2009, 9:11 http://www.biomedcentral.com/1471-2482/9/11
Page 2 of 7
(page number not for citation purposes)
Background
Intensive care units (ICUs) have played a vital role in the
practice of orthotopic liver transplantation (OLT).
Although there have been moves towards avoidance of
ICU admission after transplantation, most patients still
spend part of their post-operative course in the ICU.[1,2]
A variety of scoring systems have been used to quantify
the severity of illness of patients admitted to the ICU and
to predict their chances of survival to ICU and hospital
discharge.[3] Such prognostic scoring systems include the
Simplified Acute Physiology Score (SAPS), the Mortality
Probability Model (MPM) and the Acute Physiology and
Chronic Health Evaluation (APACHE) scoring system. [4-
6] APACHE was introduced in the early 1980s and while
minor modifications have been made over the years, only
3 major revisions have occurred. [6-8] APACHE III, origi-
nally published in 1991, has been used in a significant
number of ICUs, especially in the United States, for the
past 15 years.[8]
Mortality prediction models are likely to under- or over-
estimate mortality in selected patient subpopulations
which were not well-represented in the original cohort.
For example, studies of kidney transplant recipients and
patients with malignancies admitted to the ICU have
shown the inability of the APACHE and SAPS scoring sys-
tems to accurately predict mortality in these patient
groups. [9-12]
Of the cohort of 17,440 patients used for the development
and validation of the original APACHE III prognostic
model only 40 patients were admitted to the ICU after
OLT.[8] Between 4000 and 5000 OLTs are performed
every year in the United States. While an older version of
the APACHE scoring system, (APACHE II) has been stud-
ied in patients after OLT, the predictive ability of the
APACHE III and IV systems has not been exam-
ined.[10,13-15]
The aim of our study was to validate the APACHE III scor-
ing system in a large cohort of patients admitted to the
ICU of a tertiary referral center immediately after OLT. In
addition we aimed to evaluate the impact of the addition
of other variables (e.g. the Model for End-Stage Liver Dis-
ease, MELD) on the predictive ability of APACHE. Prog-
nostic systems have been used to justify the development
of progressive care units by identification of a group of
ICU patients at low risk for mortality. [16-18] Such sys-
tems may also provide objective assessment for the devel-
opment of ICU discharge criteria and may identify those
patients likely to require ICU readmission.[19] Both of
these issues were of interest to our institutional leadership
at the time of the study.
The liver transplant program at Mayo Clinic Rochester
began in 1985. In the immediate post-operative period,
all patients that have undergone OLT (except pediatric
patients and patients who have undergone combined liver
and heart transplantation) are cared for in the multidisci-
plinary ICU at Rochester Methodist Hospital, one of the
Mayo Clinic-affiliated hospitals in Rochester. This unit
has expanded from the original 12 beds, to 17 beds in
March 2000, and to 21 beds in April 2008. It is staffed by
a multidisciplinary critical care team who provide care to
solid organ and bone marrow transplant recipients, and
hematology and oncology, general surgery and ortho-
pedic patients. Acute ICU management of patients after
OLT is provided by senior anesthesia residents or critical
care fellows working under the supervision of board certi-
fied intensivists. Patients are managed in conjunction
with the liver transplantation service which consists of
both transplant surgeons and hepatologists. The APACHE
III scoring system has been employed in a prospective
fashion for all patients in this ICU since July 1996.
Although the APACHE IV equation for the prediction of
hospital mortality is in the public domain, other predic-
tive equations are not, and our institution has chosen not
to upgrade to the commercially-available APACHE IV
package at this time.
Methods
A retrospective cohort study was performed after Institu-
tional Review Board approval and the granting of a waiver
of informed consent. From the institutional liver trans-
plant databases adult patients who underwent OLT
between July 1996 and May 2008 were identified. For
each of the identified patients the institutional APACHE
III database was searched, using the software provided by
Cerner Corporation (Kansas City, Missouri), and
APACHE III data were abstracted. Patients who did not
authorize a review of their medical records for research
and pediatric patients were excluded. Patients who died in
the operating room or soon after arrival to the ICU were
also excluded as only patients who spend more than four
hours in the ICU generate APACHE data. Data were col-
lected for the day of ICU admission after liver transplan-
tation only. Data for second or subsequent ICU
admissions were not used.
The entry of all laboratory values used for the APACHE III
scoring was computerized using software that interfaces
with the laboratory. Vital signs, Glasgow Coma Scale
scores and urine output were abstracted by the bedside
nurses according to a formalized protocol and entered
into the computer by trained specialists. The nurses
received training, an instruction manual and initial super-
vision. Audit of the collected data for missing and discrep-
ant admission, physiologic and outcome values wasBMC Surgery 2009, 9:11 http://www.biomedcentral.com/1471-2482/9/11
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performed by experienced clinical ICU nurses. To success-
fully pass the audit, criteria were set including: at least
90% agreement on admission variables overall, 100%
agreement on admission and discharge dates, a minimum
of 80% agreement in admission diagnosis, admission and
discharge times, chronic health items, readmission status,
surgical status, active treatment status and at least 85%
agreement on overall physiology variables. Use of the
APACHE III database at our institution has been previ-
ously described.[20]
The data abstracted included age, gender, acute physiol-
ogy score (APS), APACHE III score (APIII), APACHE III-
predicted ICU and hospital mortality, and predicted
length of ICU and hospital stay. The APS and APACHE III
scores for each patient were calculated as described by
Knaus and colleagues.[8] Additionally, patients' actual
lengths of ICU and hospital stay, and ICU and hospital
discharge status (survivor versus non-survivor) and dis-
charge location were recorded.
In addition to variables abstracted from the APACHE
database, the institutional anesthesia and liver transplant
databases were searched and data regarding duration of
anesthesia and surgery and intraoperative administration
of packed red blood cells (PRBCs) were recorded for each
patient. For patients transplanted after February 2002
(when the MELD score was adopted by the United Net-
work for Organ Sharing as the basis for allocation of
donor organs), the MELD score at the time of transplanta-
tion was abstracted.
Descriptive data are summarized as mean (standard devi-
ation, SD), median (interquartile range, IQR) or percent-
age. A chi-square analysis was used to compare categorical
variables and Student's t test and rank sum tests were used
to compare continuous variables. Patients with missing
data were excluded from the analyses involving the miss-
ing data. Statistical tests were two-tailed and tests were
considered statistically significant with P < 0.05.
Standardized mortality ratios (SMRs) were calculated by
dividing the observed rates by the rates predicted by
APACHE III. The 95% confidence intervals (CI) were cal-
culated for each of the standardized mortality ratios. Dis-
crimination of a prognostic model is the ability of the
model to distinguish between survivors and non-survi-
vors. The discrimination of the APACHE III- predicted
mortality for the prediction of in-hospital mortality was
analyzed by calculating the area under the receiver operat-
ing characteristic curve (AUC).[21] An AUC of > 0.9 was
considered to be outstanding, greater than 0.8 to 0.9
excellent, 0.7 to 0.8 acceptable, and less than 0.7 was con-
sidered poor. Calibration of a model is the degree of
agreement between predicted mortality and actual mor-
tality. The Hosmer-Lemeshow C statistic was used to
determine the calibration of the model. A model with
good calibration should have a Hosmer-Lemeshow statis-
tic close to the degrees of freedom, which is equal to the
number of categories minus 2, and a P-value > 0.05.[22]
The Brier score was used as an overall assessment of the
model's performance, with a lower score indicating better
performance.[23]
Data analyses were performed using SPSS 11.5 (SPSS Inc.,
Chicago, IL) and MedCalc Version 9.1 (MedCalc Software,
Mariakerke, Belgium.)
Results
APACHE III data were available for 918 admissions after
OLT. The baseline characteristics of the subjects in the
study are shown in Table 1. The patients' mean age was
51.5 years (S.D. 10.8). Eighty-five percent were Caucasian
and 579 (63.0%) were male. The mean APIII on the day
of transplant was 60.5 (SD 25.8) and the mean APS was
50.8 (23.6). Median (IQR) lengths of ICU and hospital
Table 1: Characteristics of 918 patients who underwent 
orthotopic liver transplantation between 1996 and 2008
Age, yrs, mean (S.D) 51.5 (10.8)
Male 579
Female 339
MELD*, mean (S.D) 25.0 (7.7)
Caucasian 784 (85.5%)
Total anesthesia time (mins.), median (IQR) 384 (326, 449)
Total surgical time (mins.), median (IQR) 297 (240, 361)
Total anhepatic time (mins.), median (IQR) 75 (63, 89)
Intraop PRBCs (units), median (IQR) 5.0 (3.0, 8.0)
APS, mean (S.D.) 50.8 (23.6)
APIII, mean (S.D.) 60.5 (25.8)
Pred. number of ICU deaths (% of total) 67 (7.3%)
Actual number of ICU deaths (% of total) 10 (1.1%)
Pred. ICU LOS, median days (IQR) 4.4 (3.4, 5.7)
Actual ICU LOS, median days (IQR) 1.2 (0.9, 2.0)
Pred. number Hosp. deaths (% of total) 97 (10.6%)
Actual number Hosp. deaths (% of total) 31 (3.4%)
Pred. Hosp LOS days, median (IQR) 15.9 (13.1, 22.6)
Actual Hosp. LOS days, median (IQR) 10.4 (8.3, 18.9)
Pred Vent days, median (IQR) 3.5 (2.3, 4.1)
Survival to ICU discharge, number (% of total) 908 (98.9%)
Survival to hospital discharge, number (% of total) 887 (96.6%)
*MELD data are for 514 patients
Pred. = Predicted
LOS = Length of stay
S.D. = Standard deviation
IQR = Interquartile range
Hosp. = Hospital
ICU = Intensive Care Unit
LOS = Length of stay
APS = Acute Physiology Score
APII = Acute Physiology and Chronic Health Evaluation III
Intra-op PRBCs = Intraoperative packed red blood cells
MELD = Model for end-stage liver disease
Mins. = minutes
Yrs = yearsBMC Surgery 2009, 9:11 http://www.biomedcentral.com/1471-2482/9/11
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stay were 1.2 (0.9, 2.0) and 10.4 (8.3, 18.9) days, respec-
tively.
Mean (SD) predicted ICU and hospital mortality rates
were 7.3% (15.4) and 10.6% (18.9), respectively. The
observed ICU mortality rate was 1.1% (10 deaths of 918
patients admitted to the ICU after transplantation.) The
hospital mortality rate was 3.4% (31 deaths in 918
patients.) Thus, 21 deaths occurred in patients after dis-
charge from the ICU. These included patients in whom
support was withdrawn on the surgical floor or non-ICU
ventilator dependency unit, in whom a decision had been
made not to readmit to the ICU, or in whom a sudden
decompensation (e.g. cardiac arrest) occurred which led
to the patient's death before transfer back to the ICU. The
standardized ICU and hospital mortality ratios with their
95% C.I. were 0.15 (0.07 to 0.27) and 0.32 (0.22 to 0.45),
respectively.
MELD data were available for 514 patients. The mean
MELD score on the day of transplantation was 25.0 (SD
7.7). There was no difference in mean MELD score
between survivors and non-survivors. The median
number of PRBCs transfused was 4.0 and this was greater
in non-survivors than survivors (P < 0.01).
Among the 843 survivors to hospital discharge, 875
(91.8%) were discharged to home (as opposed to another
hospital or rehabilitation facility.) There were no signifi-
cant differences in gender (P = 0.57), race (P = 0.73) or age
(P= 0.51) between survivors and non-survivors. There
were statistically significant differences in APS, APIII, pre-
dicted ICU and predicted hospital mortality between sur-
vivors and non-survivors. In addition, the predicted and
actual ICU and hospital lengths of stay were significantly
different between survivors and non-survivors. Compari-
sons of survivors to hospital discharge and non-survivors
are in Table 2.
In predicting mortality, the AUC of APACHE III predic-
tion of hospital death was 0.65 (95% CI, 0.62 to 0.68).
The receiver operator characteristic curve is shown in Fig-
ure 1. The Hosmer-Lemeshow C statistic was 5.288 with a
P-value of 0.871 (10 degrees of freedom). The observed
and APACHE III-predicted numbers of hospital survivors
and non-survivors according to deciles of risk are given in
Table 3. The Brier score was 0.065.
Table 2: Comparison of survivors to hospital discharge and non-survivors
Survivor Non-survivor P-value
N = 887 N = 31
Age (yrs) 51.5 (10.8) 52.8 (11.0) 0.51
Male 561 18
Female 326 13 0.57
MELD* 25.0 (7.7) 25.6 (8.0) 0.78
Caucasian 757 27 0.73
Total anesthesia time (mins.) 384 (325, 447) 424 (351, 494) 0.05
Total surgical time (mins.) 295 (239, 361) 329 (254, 403) 0.09
Total anhepatic time (mins.) 75 (63, 89) 77 (66, 95) 0.7
Intra-op PRBCs (units) 4.0 (2.0, 7.0) 9.5 (4.3, 16.8) < 0.01
APS 50.3 (23.1) 66.6 (31.9) < 0.01
APIII 59.9 (25.2) 79.0 (34.5) < 0.01
Pred. ICU death %, (S.D.) 7.0 (14.8) 17.6 (25.9) < 0.01
Pred. ICU LOS days, median (IQR) 4.4 (3.4, 5.6) 5.6 (4.2, 6.7) < 0.01
Actual ICU LOS days, median (IQR) 1.2 (0.9, 2.0) 2.8 (1.1, 8.8) < 0.01
Pred Hosp death %, (S.D.) 10.2 (18.4) 22.2 (28.5) < 0.01
Pred Hosp LOS days, median (IQR) 15.8 (13.1, 22.4) 20.0 (15.3, 23.9) 0.03
Actual Hosp LOS days, median (IQR) 10.3 (8.3, 18.1) 21.2 (7.9, 37.2) 0.02
Pred ventilator days, median (IQR) 3.5 (2.3, 4.1) 3.6 (2.9, 4.3) 0.16
Values are means (standard deviation) or medians (interquartile range)
*MELD data are for 514 patients
APS = Acute Physiology Score
APII = Acute Physiology and Chronic Health Evaluation III
Pred. = Predicted
Hosp. = Hospital
ICU = Intensive Care Unit
LOS = Length of stay
Intra-op PRBCs = Intraoperative packed red blood cells
MELD = Model for end-stage liver disease
Mins. = minutes
Yrs = yearsBMC Surgery 2009, 9:11 http://www.biomedcentral.com/1471-2482/9/11
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In an effort to identify a model with better discriminatory
power while maintaining satisfactory calibration, further
analyses were performed and a series of multiple logistic
regression models were developed. In addition to inclu-
sion of the APACHE III prediction of hospital mortality,
these regression models included combinations of follow-
ing variables: duration of anesthesia, duration of surgery,
anhepatic time, number of PRBCs transfused, and MELD.
The model that included APACHE III-prediction of mor-
tality and MELD had an AUC of 0.67. A model that
included APACHE III-prediction of mortality, MELD,
anesthesia time and the number of PRBCs transfused pro-
vided a slightly higher AUC at 0.74, though this model
still had only barely acceptable discriminatory ability.
Discussion
The results from our study demonstrate that the APACHE
III prognostic scoring system poorly discriminates
between survivors and non-survivors in a large group of
patients admitted to the ICU after OLT. The AUC for
APACHE III-calculated prediction of death before hospital
discharge was only 0.65, which is not acceptable for dis-
crimination. The SMRs were very low (0.15 and 0.32 for
the ICU and hospital SMR, respectively) suggesting that
the model overestimated the mortality for a given severity
of illness. Although the Hosmer-Lemeshow statistic was
5.288 with a p value of 0.871 indicating good calibration
and the Brier score was low, the poor discriminatory abil-
ity means that the model is not robust enough to be used
for individual mortality prediction or for cohort progno-
sis.
In physiologic scoring systems, the accuracy of prediction
is not perfect and it is unreasonable to expect a very high
AUC. The best predictive models have AUCs that
approach 0.9. However, our data demonstrate that the
APACHE III system, when used for patients after OLT, falls
significantly below this desired level, and does not meet
criteria to even be deemed "acceptable" as a prognostic
tool.
A variety of factors may have contributed to the poor per-
formance of APACHE III in this population. Errors in data
acquisition, interpretation, and application of the
APACHE III equations may have been responsible. How-
ever, our experience with a large and heterogenous group
of patients at our institution suggests that we have
acquired data and implemented APACHE III prop-
erly.[20] Mortality after OLT may result from the sequelae
of rejection, which (except for primary non-function) are
unlikely to be seen during a patient's post-OLT ICU stay.
Similarly, opportunistic infection arising in the setting of
immunosuppression may lead to patient demise, though
is unlikely to manifest on the first ICU day. Intraoperative
resuscitation and therapy will "normalize" many physio-
logic derangements. As laboratory and physiologic data
acquired before admission to the ICU are not included in
calculation of the APS or APIII, ICU calculations may
underestimate the severity of illness of an OLT recipient.
Finally – and most likely the primary reason for failure of
the prognostic model – the proprietary equations from
which predictions are calculated were based on a develop-
ment cohort with few patients after OLT. The inherent
benefit of transplantation is that it has the potential to
completely reverse a patient's deteriorating physiology,
thus modifying the risk of mortality, and this benefit does
not appear to be adequately accounted for in APACHE.
Customization of prognostic scoring systems has been
attempted, because mortality predictions are often not
accurate in populations other than those in which the sys-
tems were developed because of differences in case-
mix.[24,25] Angus and colleagues customized APACHE II
(not III) for prediction of mortality in OLT recipients.
However, even their customized model had poor discrim-
ination (AUC 0.68 to 0.72).[15] Another attempt at cus-
tomization of APACHE II for use in OLT recipients by
Arabi and colleagues resulted in an improvement of dis-
crimination and calibration.[13] However, this customi-
zation has been criticized because of the use of a highly
heterogenous database and a sample size too small to use
the Hosmer-Lemeshow goodness of fit test appropri-
Receiver operator characteristic plot of hospital mortality  prediction using the APACHE III-prediction of hospital death Figure 1
Receiver operator characteristic plot of hospital 
mortality prediction using the APACHE III-predic-
tion of hospital death. AUC of APACHE III prediction of 
hospital death was 0.65 (95% CI, 0.62 to 0.68). Diagonal line 
denotes AUC = 0.5.
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ately.[26] Similar to the experiences of other investigators
with APACHE II, customization did not significantly
improve the performance of APACHE III in our study. It is
not surprising that customization of the model by inclu-
sion of the MELD score did not result in a significant
improvement in discriminatory ability. Most of the varia-
bles upon which MELD is based are already included as
part of the APACHE prediction model. (Bilirubin, creati-
nine, and the presence of renal failure or cirrhosis are
included in APACHE, though INR is not.) However, even
the addition of other variables did not provide a model
with good or excellent discriminatory ability.
There are number of limitations to our study. Patients
were cared for at a single center and may not be represent-
ative of other ICUs in other medical centers. However, the
validation of APACHE in a group of patients at a single
center may more accurately reflect the performance of the
model without the confounding influence of standards of
care at different institutions. Thus, we believe that
APACHE III is unlikely to perform better in OLT recipients
elsewhere. Similar to other investigators using earlier
models of APACHE, the calibration of the model was
good. This is interesting, as the calibration of scoring sys-
tems usually declines over time.[3] However, the low
number of deaths limits the power of the calibration anal-
ysis. The population studied was devoid of racial diversity
as it comprised a large number of Caucasians. While this
reflects the referral practice of our institution, it may limit
the generalizability of our findings. There was a variety of
etiologies for liver failure in our patient population and
APACHE may perform better in certain disease states,
though we did not have a sufficient patient population to
test this hypothesis. Furthermore, heterogeneity of the
populations in the pre- and post- MELD era may also be a
confounding factor. The exclusion of patients who died in
the operating room or within four hours of ICU admis-
sion because they did not generate APACHE data may
have further limited our analyses.
Conclusion
The APACHE III scoring system discriminates poorly
between survivors and non-survivors of patients admitted
to the ICU after OLT. Customization of APACHE III,
including the addition of MELD, did not result in accept-
able discrimination of the model. Though APACHE III has
been shown to be valid in heterogenous populations and
in certain groups of patients with specific diagnoses, it
should be used with caution – if used at all – in recipients
of liver transplantation.
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